AGC Biologics

AGC Biologics

AGC Biologics

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem. Sign in

AGC Biologics

Address

Czernyring 22
69115 Heidelberg, Germany

Contact

contactus@agcbio.com

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem.

Matchmaking

Connect with AGC Biologics

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

AGC Biologics last news

13/06/2024

Siegfried nabs US site from Curia; Merck KGaA pumps €62M more into its HQ

Welcome to Endpoints News' manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Siegfried is acquiring a manufacturing facility in Grafton, WI, from the CDMO Curia Global, adding to its current network of 12 sites. Siegfried will also gain over 80 staffers working at the Grafton site. The transaction is expected to close in July. Siegfried said Wednesday that the facility will provide services in early-phase manufacturing including high-potency active pharmaceutical ingredients. Merck KGaA is pouring €62 million ($67 million) into its Darmstadt headquarters in Germany for a new quality control building. The new facility will hire around 135 employees. The building will be finished by mid-2025, according to a June 6 release. NorthStar Medical Radioisotopes and Monopar Therapeutics are updating their existing partnership, which saw Northstar supply the isotope actinium-225 to Monopar for its lead solid cancer candidate, dubbed MNPR-101. Under the updated partnership, Monopar will gain complete ownership of MNPR-101 and NorthStar will supply Ac-225 for future investigations, according to a Tuesday release. AGC Biologics is manufacturing Essential Pharma's monoclonal antibody for high-risk neuroblastoma, the companies announced Tuesday. Dec Group is acquiring the German arm of Bausch, which specializes in aseptic fill-finish packaging. Bausch Germany will become a subsidiary of Dec, according to a Wednesday release. UPS Healthcare is expanding its European hub in Roermond, the Netherlands, which will add space for over 200 ultra-low temperature freezers that can store products at -80°C, the company told Endpoints News . Private equity firm Thompson Street Capital Partners is merging two companies in its portfolio: Vector Laboratories and Absolute Biotech. Vector manufactures reagents and components of life science tools, diagnostic products and clinical-stage therapies. Absolute Biotech is an antibody manufacturer. Lisa Sellers, CEO of Vector, will run the merged company, a Tuesday release said. Alvotech and STADA are extending their existing partnership to include STADA's investigational biosimilar AVT03. The candidate is being studied as a biosimilar for denosumab, which is approved to help decrease bone resorption and cancer-related bone damage. Alvotech will manufacture the asset at its site in Reykjavik, Iceland, according to a Monday release.

12/06/2024

AGC Biologics & Chief Executive Officer Patricio Massera Announce Plans for Him to Step Down

SEATTLE--News Direct--AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced that its Chief Executive Officer (CEO), Patricio Massera, will be

11/06/2024

AGC Biologics Doubles Single-Use Bioreactor Capacity with Expansion at Denmark Site

AGC Biologics has completed an expansion at its Copenhagen, Denmark, site, which doubles its bioreactor capacity for mammalian-based cell culture.